Profil
Patrick Chaltin is currently Director at Cytura Therapeutics BV and Managing Partner at Centre for Drug Design & Discovery.
Formerly, Dr. Chaltin was Non-Executive Director at Aratana Therapeutics NV.
Dr. Chaltin earned a doctorate from Katholieke Universiteit Leuven.
Postes actifs de Patrick Chaltin
| Sociétés | Poste | Début |
|---|---|---|
Cytura Therapeutics BV
Cytura Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing biotechnology | Directeur/Membre du Conseil | - |
Centre for Drug Design & Discovery
Centre for Drug Design & Discovery Investment ManagersFinance Centre for Drug Design & Discovery is an active manager which invests in companies located in Belgium. It participates in seed stage and early stage transactions and focuses on the Health Technology sector. | Private Equity Investor | - |
Anciens postes connus de Patrick Chaltin
| Sociétés | Poste | Fin |
|---|---|---|
Aratana Therapeutics NV
Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Develops and markets drugs to treat viral infections in both pet animals and livestock | Directeur/Membre du Conseil | - |
Formation de Patrick Chaltin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aratana Therapeutics NV
Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Develops and markets drugs to treat viral infections in both pet animals and livestock | Health Technology |
Cytura Therapeutics BV
Cytura Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing biotechnology | Commercial Services |
Centre for Drug Design & Discovery
Centre for Drug Design & Discovery Investment ManagersFinance Centre for Drug Design & Discovery is an active manager which invests in companies located in Belgium. It participates in seed stage and early stage transactions and focuses on the Health Technology sector. | Finance |
















